24% Overvalued? Xeris Biopharma Holdings (XERS) Following Raised 2026 Guidance

Xeris Biopharma Holdings (XERS) paired a stronger third quarter with higher full year 2026 revenue guidance, giving investors fresh information on both recent performance and management’s expectations for the rest of the year.

The earnings surprise and raised 2026 outlook have arrived alongside sharp share price momentum. Xeris Biopharma Holdings has logged a 1-day share price return of 16.21% and a 90-day gain of 91.68%, while the 3-year total shareholder return of about 8x signals that longer term holders have already seen very large gains. This suggests that expectations and perceived risk are both shifting quickly around the US$15.20 share price.

Surf 19 high quality undiscovered gems hand picked for biopharma investors who see Xeris Biopharma Holdings’ earnings surprise and guidance shift as a cue to look for the next under the radar rerating.

After a move this sharp on the back of Xeris Biopharma Holdings’ guidance shift, the real tension is simple: Does the current valuation still leave enough upside to justify fresh risk?

Most Popular Narrative: 24% Overvalued

The most followed valuation narrative for Xeris Biopharma Holdings pegs fair value at $12.29, which sits meaningfully below the recent $15.20 close. As a result, the market is now assigning a richer price than that framework supports.

The impending launch of XP-8121, which utilizes proprietary delivery technology to address a significant unmet need in hypothyroidism, opens the door to a high-value market segment underserved by innovation, potentially driving new revenue streams and long-term margin expansion.

See why 9 investors see Xeris Biopharma Holdings as 24% overvalued.

Result: Fair Value of $12.29 (OVERVALUED)

Still, concentrated dependence on Recorlev and XP-8121, along with rising R&D and SG&A, could quickly challenge the current Xeris Biopharma Holdings narrative.

Find out about the key risks to this Xeris Biopharma Holdings narrative.

Another View: SWS DCF Flags Xeris Biopharma Holdings As Undervalued

The analyst narrative pins Xeris Biopharma Holdings at a fair value of $12.29 and labels the stock overvalued at $15.20. Our DCF model presents a different perspective. It pegs future cash flow value at $25.70, which frames the same price as undervalued instead. Which playbook do you trust?

For readers who want to unpack how this cash flow view is built, Look into how the SWS DCF model arrives at its fair value..

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Xeris Biopharma Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 39 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Conflicted about whether Xeris Biopharma Holdings is priced for perfection or still leaves room for upside, given both flagged risks and potential rewards? Move quickly, review the underlying data, and weigh the 3 key rewards and 1 important warning sign against your own judgment before you decide what happens next.

Looking for more investment ideas beyond Xeris Biopharma Holdings?

If Xeris Biopharma Holdings has your attention after this latest update, do not stop here. Broaden your opportunity set with a few focused stock lists built to surface candidates you might otherwise miss.

• Target potential mispricing by reviewing a curated set of companies that screen as quality yet out of favor through the 39 high quality undervalued stocks.
• Prioritize resilience and capital strength by scanning the list of solid balance sheet and fundamentals (24 results) that filters for sturdier balance sheets and healthier fundamentals.
• Hunt for early stage opportunities that still fly under most radars by checking the 9 elite penny stocks with strong financials before the crowd starts paying attention.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com